Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...

Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly delaying market entry of generic Pomalyst | Lawsuit follows dismissal of ...

US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of ...

Pomalyst was originally approved in 2013 and is not expected to face generic competition until next year. In 2024, the product generated revenue of $3.5 billion worldwide, ...

Pomalyst can cause certain adverse effects (side effects), some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. But if the side effects last ...

Pomalyst is a prescription drug used to treat multiple myeloma and Kaposi sarcoma. Learn about the drug’s dosages, form, strengths, and more.

Pomalyst appears to be on track to eventually hit annual sales between $1 billion and $2 billion. If that happens, the drug would by far eclipse the success of Thalomid.

Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it ...